TY - JOUR
T1 - Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes
AU - Invernizzi, Rosangela
AU - Travaglino, Erica
AU - De Amici, Mara
AU - Brugnatelli, Silvia
AU - Ramajoli, Isabella
AU - Rovati, Bianca
AU - Benatti, Chiara
AU - Ascari, Edoardo
PY - 2005/6
Y1 - 2005/6
N2 - We treated with thalidomide seven patients with primary MDS and observed reduction of the transfusion requirement in three cases and reduction of bone marrow blasts in one case. The apoptotic rate of bone marrow cells diminished significantly from a mean of 43.8% to a mean of 17.5%, whereas the proliferative activity did not change. Plasma TNF-α, bFGF, IL-1β levels decreased variably, whereas VEGF levels tended to increase. Matrix metalloproteinases 2 and 9 expression decreased in bone marrow cells of responders. A reduction of CD4 cells and an increase of NK cells was observed in the peripheral blood. Thus, thalidomide may produce a fairly good hematological improvement in erythroid series in MDS, with complex biological mechanisms.
AB - We treated with thalidomide seven patients with primary MDS and observed reduction of the transfusion requirement in three cases and reduction of bone marrow blasts in one case. The apoptotic rate of bone marrow cells diminished significantly from a mean of 43.8% to a mean of 17.5%, whereas the proliferative activity did not change. Plasma TNF-α, bFGF, IL-1β levels decreased variably, whereas VEGF levels tended to increase. Matrix metalloproteinases 2 and 9 expression decreased in bone marrow cells of responders. A reduction of CD4 cells and an increase of NK cells was observed in the peripheral blood. Thus, thalidomide may produce a fairly good hematological improvement in erythroid series in MDS, with complex biological mechanisms.
KW - Angiogenic cytokines
KW - Apoptosis
KW - Lymphocyte subsets
KW - Matrix metalloproteinases
KW - Myelodysplastic syndromes
KW - Thalidomide
UR - http://www.scopus.com/inward/record.url?scp=18044393194&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=18044393194&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2004.11.008
DO - 10.1016/j.leukres.2004.11.008
M3 - Article
C2 - 15863203
AN - SCOPUS:18044393194
VL - 29
SP - 641
EP - 647
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 6
ER -